Clinical Trials on Extracapillary Glomerulonephritis in United Kingdom

Total 223 results

Imperial College Healthcare NHS Trust

Completed

Mycophenolate Mofetil and Tacrolimus Versus Tacrolimus for the Treatment of Idiopathic Membranous Glomerulonephritis (MTAC)

Glomerulonephritis, Membranous

United Kingdom
Alexion Pharmaceuticals

Completed

A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G)

C3 Glomerulopathy | C3 Glomerulonephritis | Dense Deposit Disease

United Kingdom, United States
BioCryst Pharmaceuticals

Terminated

BCX9930 for the Treatment of C3G, IgAN, and PMN (RENEW)

Immunoglobulin A Nephropathy | Membranous Nephropathy | Complement 3 Glomerulopathy

France, Italy, Spain, United Kingdom
Manchester University NHS Foundation Trust
Fresenius AG

Completed

Peptide GAM Immunoadsorption Therapy in Autoimmune Membranous Nephropathy (PRISM)

Autoimmune Membranous Nephropathy

United Kingdom
GlaxoSmithKline

Completed

A Study of Belimumab in Idiopathic Membranous Glomerulonephropathy

Glomerulonephritis, Membranous

United Kingdom
Charite University, Berlin, Germany
Berlin Institute of Health

Active, not recruiting

Urinary T Cell Biomarker for Prediction in ANCA Glomerulonephritis

Glomerulonephritis Acute

United Kingdom, Germany
Apellis Pharmaceuticals, Inc.

Active, not recruiting

An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis (VALE)

C3G | IC-MPGN | C3 Glomerulopathy | C3 Glomerulonephritis | Complement 3 Glomerulopathy | Complement 3 Glomerulopathy (C3G) | Complement 3 Glomerulonephritis | Dense Deposit Disease | DDD | Membranoproliferative Glomerulonephritis | Membranoproliferative Glomerulonephritis (MPGN) | Immune Complex Membranoproliferative...

United States, Australia, Brazil, Czechia, France, Italy, Korea, Republic of, Netherlands, Spain, Switzerland, United Kingdom
Celldex Therapeutics

Terminated

Clinical Trial of CDX-1135 in Pediatric and Adult Patients With Dense Deposit Disease

C3 Glomerulonephritis | Dense Deposit Disease | Membranoproliferative Glomerulonephritis Type II

United States
Apellis Pharmaceuticals, Inc.

Active, not recruiting

Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN (NOBLE)

Renal Transplant | C3G | IC-MPGN | C3 Glomerulopathy | C3 Glomerulonephritis | Complement 3 Glomerulopathy | Complement 3 Glomerulopathy (C3G) | Complement 3 Glomerulonephritis | Membranoproliferative Glomerulonephritis | Membranoproliferative Glomerulonephritis (MPGN) | Immune Complex Membranoproliferative... and other conditions

United States, Australia, Austria, United Kingdom, Brazil, Argentina, France, Italy, Netherlands, Spain, Switzerland
University of Leicester
Travere Therapeutics, Inc.

Active, not recruiting

A Study of the Safety and Activity of Sparsentan for the Treatment of Incident Patients With Immunoglobulin A Nephropathy (SPARTAN)

Immune System Diseases | Autoimmune Diseases | Kidney Diseases | Glomerulonephritis | Immunoglobulin A Nephropathy | Glomerulonephritis, IGA

United Kingdom
Mayo Clinic

Completed

Pilot Study of Rituximab for Membranoproliferative Glomerulonephritis

Glomerulonephritis, Membranoproliferative

United States
Apellis Pharmaceuticals, Inc.

Available

C3G/Primary IC-MPGN EAP

C3G | IC-MPGN | C3 Glomerulopathy | C3 Glomerulonephritis | Complement 3 Glomerulopathy | Complement 3 Glomerulopathy (C3G) | Complement 3 Glomerulonephritis | Dense Deposit Disease | DDD | Membranoproliferative Glomerulonephritis | Membranoproliferative Glomerulonephritis (MPGN) | Immune Complex Membranoproliferative...

United States
Columbia University
Alexion Pharmaceuticals

Completed

Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy

Dense Deposit Disease | Membranoproliferative Glomerulonephritis

United States
Fernando Fervenza

Completed

Daratumumab in Treatment of PGNMID and C3 GN

Membranoproliferative Glomerulonephritis

United States
Alnylam Pharmaceuticals

Terminated

A Study of Cemdisiran in Adults With Immunoglobulin A Nephropathy (IgAN)

IgA Nephropathy (IgAN) | Berger Disease | Glomerulonephritis, IgA

Canada, Malaysia, France, Sweden, United Kingdom, Philippines, Singapore, Spain, Taiwan
Apellis Pharmaceuticals, Inc.

Active, not recruiting

Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis (VALIANT)

C3G | IC-MPGN | C3 Glomerulopathy | C3 Glomerulonephritis | Complement 3 Glomerulopathy | Complement 3 Glomerulopathy (C3G) | Complement 3 Glomerulonephritis | Dense Deposit Disease | DDD | Membranoproliferative Glomerulonephritis | Membranoproliferative Glomerulonephritis (MPGN) | Immune Complex Membranoproliferative...

United States, Spain, France, Germany, United Kingdom, Netherlands, Brazil, Israel, Japan, Australia, Austria, Italy, Switzerland, Korea, Republic of, Czechia, Belgium, Argentina, Canada, Poland
Novartis Pharmaceuticals

Terminated

Efficacy and Safety of LNP023 Compared With Rituximab in Subjects With Idiopathic Membranous Nephropathy

Glomerulonephritis, Membranous

Czechia, India, Taiwan, United Kingdom, Germany, Argentina, China, Netherlands, Spain
Omeros Corporation

Recruiting

Safety and Efficacy Study of OMS906 in Patients With C3G and ICGN

C3 Glomerulopathy | Idiopathic Immune Complex-Mediated Glomerulonephritis

Lithuania, New Zealand, Poland, Tunisia, Turkey, United Kingdom
Rigel Pharmaceuticals

Completed

Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy

IGA Nephropathy

United States, United Kingdom, Hong Kong, Taiwan, Austria, Germany
Mayo Clinic
Genentech, Inc.

Completed

Pilot Study of Rituximab to Treat Fibrillary Glomerulonephritis

Fibrillary Glomerulonephritis

United States
Cambridge University Hospitals NHS Foundation Trust

Withdrawn

Steroids in the Maintenance of Remission of Proliferative Lupus Nephritis (SIMPL)

Lupus Nephritis

United Kingdom
Alexion

Terminated

A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471

IC-MPGN | C3 Glomerulopathy | C3 Glomerulonephritis | Dense Deposit Disease | Immune Complex Membranoproliferative Glomerulonephritis

United States, Australia, Belgium, Italy, Netherlands
Anthera Pharmaceuticals

Completed

BRIGHT-SC: Blisibimod Response in IgA Nephropathy Following At-Home Treatment by Subcutaneous Administration

IgA Nephropathy

Czechia, Germany, Hong Kong, Korea, Republic of, Malaysia, Philippines, Singapore, Taiwan, Thailand, United Kingdom
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Terminated

Efficacy and Safety of Atacicept in IgA Nephropathy

IgA Nephropathy

United States, Japan, United Kingdom
Charite University, Berlin, Germany
Berlin Institute of Health

Active, not recruiting

Urinary T Cell Biomarker for Prediction in Lupus Nephritis

Lupus Nephritis

Germany, United Kingdom
Apellis Pharmaceuticals, Inc.

Active, not recruiting

Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies

Lupus Nephritis | IgA Nephropathy | Membranous Nephropathy | C3 Glomerulonephritis | Dense Deposit Disease

United States
National Center for Research Resources (NCRR)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Ohio...

Completed

Study of Genetic Anomalies of Complement Related Proteins in Patients With IgA Glomerulonephritis

IGA Glomerulonephritis

United States
University of Iowa

Withdrawn

TP10 Use in Patients With C3 Glomerulopathy (C3G)

Dense Deposit Disease

United States
University of Iowa

Withdrawn

Sulodexide Treatment in Patients With Dense Deposit Disease

Dense Deposit Disease

United States
Mayo Clinic
Genentech, Inc.

Completed

Rituximab in the Treatment of Idiopathic Membranous Nephropathy

Membranous Nephropathy

United States
National Institute of Diabetes and Digestive and...

Completed

Sirolimus Therapy for Idiopathic and Lupus Membranous Nephropathy

Membranous Glomerulonephritis | Lupus Membranous Nepropathy

United States
GlaxoSmithKline

Withdrawn

Efficacy and Safety Study of Intravenous Belimumab Versus Placebo in Subjects With Idiopathic Membranous Nephropathy

Glomerulonephritis, Membranous

Australia, Spain, United States, Canada, Germany, Netherlands, France, United Kingdom, Czech Republic, Italy
Mayo Clinic
Genentech, Inc.

Completed

Rituximab in Membranous Nephropathy

Membranous Nephropathy

United States
Chinook Therapeutics, Inc.

Active, not recruiting

Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN)

IgA Nephropathy

Korea, Republic of, United States, United Kingdom
HI-Bio

Completed

Efficacy, Safety and PK/PD of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN) (NewPLACE) (NewPLACE)

Glomerulonephritis | Membranous Nephropathy | antiPLA2R Positive

Taiwan, Korea, Republic of, Greece, Germany, United Kingdom, Georgia, Russian Federation
Genzyme, a Sanofi Company

Completed

Safety Study of GC1008 in Patients With Focal Segmental Glomerulosclerosis (FSGS) of Single Doses of GC1008 in Patients With Treatment Resistant Idiopathic FSGS

Focal Segmental Glomerulosclerosis

United States, Germany, United Kingdom, Italy
NephroNet, Inc.
Mallinckrodt

Active, not recruiting

A Study of Acthar Gel Alone or With Tacrolimus to Reduce Proteinuria in Fibrillary Glomerulopathy Patients (FACT)

Fibrillary Glomerulonephritis

United States
Icahn School of Medicine at Mount Sinai

Completed

Adrenocorticotropic Hormone in Membranous Nephropathy

Membranous Nephropathy

United States
St. Joseph's Hospital and Medical Center, Phoenix

Terminated

Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy

IgA Nephropathy

United States
Aravive, Inc.

Terminated

Study of Safety and Efficacy of AVB-S6-500 in Patients With IgA Nephropathy

IgA Nephropathy

United States, Ukraine
Arrowhead Pharmaceuticals

Recruiting

Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease

IgA Nephropathy | C3 Glomerulopathy

New Zealand, Australia, Korea, Republic of, Thailand, Germany, United Kingdom, Georgia
Visterra, Inc.

Completed

First in Human Study to Assess Safety of VIS649 in Healthy Subjects

Immunoglobulin A Nephropathy | IgA Nephropathy | IgAN - IgA Nephropathy

United States
Mayo Clinic

Withdrawn

Aliskiren in Patients With Idiopathic Membranous Nephropathy

Idiopathic Membranous Nephropathy

United States
Mayo Clinic

Not yet recruiting

Obinutuzumab in Treatment of Fibrillary Glomerulonephritis

Fibrillary Glomerulonephritis

United States
UK Kidney Association

Recruiting

National Registry of Rare Kidney Diseases (RaDaR)

Vasculitis | AL Amyloidosis | Tuberous Sclerosis | Fabry Disease | Cystinuria | Focal Segmental Glomerulosclerosis | IgA Nephropathy | Bartter Syndrome | Pure Red Cell Aplasia | Membranous Nephropathy | Atypical Hemolytic Uremic Syndrome | Autosomal Dominant Polycystic Kidney Disease | Cystinosis | Nephronophthisis | BK Nephropathy and other conditions

United Kingdom
Gilead Sciences

Completed

Study to Evaluate the Safety and Efficacy of Filgotinib and Lanraplenib in Adults With Lupus Membranous Nephropathy (LMN)

Lupus Membranous Nephropathy

United States
Mayo Clinic
Columbia University; Genentech, Inc.; Stanford University; Ohio State University; Bioge... and other collaborators

Completed

Rituximab in Progressive Immunoglobulin A (IgA) Nephropathy

IgA Nephropathy

United States
Novartis Pharmaceuticals

Completed

Study of Safety and Efficacy of LNP023 in Patients With Kidney Disease Caused by Inflammation

IgA Nephropathy

Colombia, Taiwan, Czechia, India, Turkey, Belgium, Netherlands, Singapore, Australia, Korea, Republic of, Thailand, Argentina, Germany, Israel, Japan, Sweden, United Kingdom, Brazil, China, Hong Kong, Norway, Finland, France, Denmark, M...
Mayo Clinic
Mallinckrodt

Completed

Dose-Finding Pilot Study of ACTH in Patients With Idiopathic Membranous Nephropathy (MN)

Idiopathic Membranous Nephropathy

United States, Canada
Baylor College of Medicine

Withdrawn

Acthar on Proteinuria in IgA Nephropathy Patients

Proteinuria | IgA Nephropathy

United States

Clinical Trials on Extracapillary Glomerulonephritis in United Kingdom

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Turkmenistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations